The Readout LOUD

The Readout LOUD Damian Garde and Allison DeAngelis

Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump

The Readout LOUD Damian Garde and Allison DeAngelis

A thorny ALS debate at the FDA, and the promise of artificial wombs

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Covid’s latest surge, Alnylam at the FDA, & the end of an era

The Readout LOUD Damian Garde and Adam Feuerstein

Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Vivek’s star turn, leaky drug data, & biotech as family business

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Your guide to Wegovy’s blockbuster heart study

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Biogen’s sticky situation, Wegovy’s risks, & biotech insider trading

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market

The Readout LOUD Damian Garde and Meg Tirrell

Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Biogen’s messy board, Laronde’s data problem, & the downside of a boom

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Fake medical devices, real cancer drugs, & curious Ozempic effects

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: The FTC v. Amgen, Sarepta’s future, & Galapagos’ turnaround

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Sarepta’s pivotal moment, biotech’s big week, & the future of Covid boosters

The Readout LOUD Damian Garde and Meg Tirrell

Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

The Readout LOUD Damian Garde and Meg Tirrell

Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle